Magazine Article | September 1, 2022

The "Liberation" Of Science Yields A New Class Of Biopharma Leadership

Source: Life Science Leader

By Matthew Pillar, Editor, Bioprocess Online

Current bear market in emerging biotech notwithstanding, there’s a longer-term trend in the biopharma space that’s inciting a bit of a talent exodus from Big Pharma to emerging bio. On episode 95 of the Business of Biotech podcast, Purespring Therapeutics CEO Richard Francis called that trend the “liberation” of science as he shared his motivation for leaving a C-suite career among the likes of Biogen, Sandoz, and Novartis for the challenge of leading a brand-new biopharma startup.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader